AsianScientist (Oct. 29, 2013) – Advanced Cell Diagnostics, Inc. (ACD) and Kindstar Global (Kindstar) have announced that Kindstar will be validating and implementing ACD’s RNAscope® technology-based molecular diagnostic assays in its clinical laboratories.
The initial suite of tests to be launched include RNAscope HPV, a high-risk HPV test to determine HPV status in cervical pre-cancer and head & neck cancer, and CTCscope, a blood-based test to detect and characterize circulating tumor cells in blood.
This partnership will enable Kindstar, a company specializing in esoteric lab tests, to leverage ACD’s RNA biomarker analysis platform to offer a new generation of cancer diagnostic tests to its network of more than 3,300 hospitals across China.
“Kindstar is excited to offer services in China based on the most advanced RNA in situ hybridization platform in the industry. The new RNAscope-based tests will significantly broaden Kindstar’s oncology test menu offerings,” said Dr. Shiang Huang, founder and CEO of Kindstar. “The RNAscope platform will also allow Kindstar to more rapidly translate today’s advances in cancer research into clinical practice for our physicians and patients.”
——
Source: Advanced Cell Diagnostics.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
